Evaluations › COHERE · Last reviewed 2026-05-16

COHERE Finland (June 2020)

Co-architect: Riittakerttu Kaltiala. Position in chronology: timeline 2020-06.

Summary

The Finnish Council for Choices in Health Care (COHERE / Palveluvalikoimaneuvosto) issued a recommendation on the medical treatment of gender dysphoria in minors in 2020. As summarised by the Cass Review, the Finnish guideline names psychosocial care as first-line treatment, proposes extreme caution with puberty blockers under the age of 18 and recommends puberty suppression under a research protocol or the supervision of a research clinic (source).

Key points

  • Psychosocial care as first-line treatment (source).
  • Extreme caution with puberty blockers under the age of 18 (source).
  • Puberty suppression under a research protocol or the supervision of a research clinic (source).
  • Conclusions on the uncertainty of the evidence similar to those of the Swedish guideline (source).

Rationale

In its appraisal of international guidelines, the research team for the Cass Review found that most guidelines had not followed the international standards for guideline development and could recommend only two for practice: the Finnish guideline of 2020 and the Swedish guideline of 2022 (source).1

See also

Footnotes

  1. Palveluvalikoimaneuvosto (COHERE Finland). Recommendation on medical treatment of gender dysphoria in minors, 2020; as summarised in: Cass H. Independent review of gender identity services for children and young people: final report. NHS England; 2024 (paragraphs 9.35, 11.14, 14.16).